Vir Biotechnology Presents New Data Evaluating the Potential

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D - Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D - Vir Biotechnology (NASDAQ:VIR)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Auckland , New Zealand , Fung Yuen , Carey Hwang , Florian Lempp , Edward Gane , Marka Schmidt , Snehav Gupta , University Of Hong Kong , Clinical Research , Division Of Gastroenterology , Vir Biotechnology Inc , Alnylam Pharmaceuticals Inc , Kaiser Permanente Center , University Of Auckland , Health Research , European Association , Professor Man Fung Yuen , Hong Kong , Senior Vice President , Breaker Oral Presentation , Man Fung Yuen , Chief Hepatologist , Transplant Physician , Deputy Director , New Zealand Liver Transplant Unit , Auckland City , Poster Presentations , Clinical Pharmacology , Infectious Disease Epidemiologist , Enhanced Stabilization Chemistry Plus , Alnylam Pharmaceuticals ,